BioSpace News Archive

Henlius released a positive profit forecast. Based on the preliminary assessment of the unaudited comprehensive management accounts for the six months ended June 30, 2023, the company expects to turn into profits in the first half of 2023, achieving profitability for the first time in a six-month period.

Bionomics Limited announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth.

Skyline Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Phase I/IIa clinical trial of SKG0106.

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting held earlier today, all resolutions were duly passed on a show of hands.

Camena Bioscience announced it has closed a $10m Series A financing round, led by Mercia.

AlzeCure Pharma AB a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that a new scientific article on preclinical results supporting antidepressive effects with NeuroRestore ACD856 has been published.

Fresenius Kabi announced today the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira® (adalimumab).

Nicox SA announced that additional data on NCX 470 have been presented at the 10th World Glaucoma Congress (WGC) being held from June 28 to July 1, 2023 in Rome, Italy.

DEKA, a subsidiary of the El.En. Group, a company listed on the Eurostar Next of the Italian Stock Exchange, specialized in the development and manufacturing of cutting-edge Energy Based Devices for Aesthetics and Surgery, has announced the launch of its new “PRO” line, based on laser and microwave devices, at the 25th WCD Congress, which will be held in Singapore from July 3 until July 8.

Zealand Pharma A/S announced results from Part 1 of a multiple ascending dose trial for ZP8396, the company’s long-acting amylin analog with potential for the management of overweight and obesity.